Condition: HER2-Gastric/Gastroesophageal Junction Cancer · Urothelial Carcinoma · Non-Small Cell Lung Cancer · Sponsor: Abbisko Therapeutics Co, Ltd
The purpose of this study is to evaluate the anti-tumor activity of ABSK061 + ABSK043 in terms of overall response rate (ORR) in in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations
This description comes directly from the study's public registry record.
Yuan Lu, Doctor · +86(21)68910052 · clinical@abbisko.cn
Always discuss trial participation with your own doctor first.
| Guizhou Provincial People'S Hospital | Guiyang, Guizhou, China | Not Yet Recruiting |
| The Affiliated Hospital of Guizhou Medical University | Guiyang, Guizhou, China | Not Yet Recruiting |
| The Fourth Hospital of Hebei Medical University | Shijiazhuang, Heibei, China | Not Yet Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Not Yet Recruiting |
| Hunan Central Hospital | Changsha, Hunan, China | Not Yet Recruiting |
| Jiangxi Cance Hospital | Nanchang, Jiangxi, China | Not Yet Recruiting |
| Liaoning Cancer Hospital and Institute | Shenyang, Liaoning, China | Not Yet Recruiting |
| Cancer Hospital of Shandong First Medical University | Jinan, Shandong, China | Not Yet Recruiting |
| ZhongShan Hospital Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
| Xiangyang Central Hospital | Xiangyang, Sichuang, China | Not Yet Recruiting |
| Changzhi People's Hospital | Changzhi, China | Not Yet Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06632262